Deferasirox: A comprehensive drug profile

Profiles Drug Subst Excip Relat Methodol. 2024:49:1-18. doi: 10.1016/bs.podrm.2023.11.001. Epub 2024 Jan 22.

Abstract

Deferasirox is an iron-chelating drug developed by Novartis company for treatment of diseases accompanied by chronic iron overload; such as β-thalassemia or sickle cell diseases. Owing to its advantages such as high affinity, specificity and wide therapeutic window, it is considered as first line treatment. The current chapter describes the physicochemical characteristics, mode of action, pharmacokinetics, therapeutic applications and synthetic methods for deferasirox. Moreover, it includes Fourier transform infrared spectrometry (FTIR) and nuclear magnetic resonance spectroscopy (NMR) analysis for its functional groups. In addition, the selected analytical methods are summarized to aid the analysts in their routine analysis of deferasirox.

Keywords: Analysis; Deferasirox; Methods of chemical synthesis; Pharmacokinetics; Pharmacological effects.

MeSH terms

  • Benzoates* / metabolism
  • Benzoates* / pharmacology
  • Benzoates* / therapeutic use
  • Deferasirox / pharmacology
  • Deferasirox / therapeutic use
  • Humans
  • Iron / metabolism
  • Iron / therapeutic use
  • Iron Chelating Agents / metabolism
  • Iron Chelating Agents / pharmacology
  • Iron Chelating Agents / therapeutic use
  • Iron Overload* / drug therapy
  • Triazoles / pharmacokinetics
  • Triazoles / therapeutic use

Substances

  • Deferasirox
  • Benzoates
  • Triazoles
  • Iron Chelating Agents
  • Iron